NI, Yong,PARIKH, Bhavnish,YELESWARAM, Krishnaswamy,ERICKSON-VIITANEN, Susan,WILLIAMS, William V.
申请号：
AU2018203899
公开号：
AU2018203899A1
申请日:
2018.06.01
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
#$%^&*AU2018203899A120180621.pdf#####ABSTRACT The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.1/4 FIGURE 1 -0- 25 mg IR 1000--A-- 25 mg SR-1 -+-25mg SR-2 100 6 12 18 24 30 36 Time (h)
